USPTO Examiner YAO LEI - Art Unit 1642

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18749771COMPOSITIONS AND METHODS FOR DETECTING PANCREATIC CANCERJune 2024June 2025Allow1211YesNo
18405910BINDING MOLECULESJanuary 2024June 2024Allow601YesNo
18501589Tetravalent FZD and WNT Co-receptor Binding Antibody Molecules and Uses ThereofNovember 2023January 2025Abandon1511YesNo
18381344INTRACELLULAR DELIVERY COMPOSITIONSOctober 2023April 2025Allow1821YesNo
18060455USE OF TENASCIN-C AS AN EXTRACELLULAR MARKER OF TUMOR-DERIVED MICROPARTICLESNovember 2022June 2025Allow3030YesNo
17895295ANTI-PSMA ANTIBODIES AND USES THEREOFAugust 2022February 2024Allow1711YesNo
17819483ANTI-LAMBDA MYELOMA ANTRIGEN (LMA) BINDING PROTEINS TO TREAT LMA-EXPRESSING CANCER AND AUTOIMMUNE DISORDERSAugust 2022April 2025Allow3301NoNo
17876899A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSJuly 2022October 2022Allow300YesNo
17868368A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSJuly 2022September 2022Allow200YesNo
17851277RECOMBINANT ANTIBODY AND USES THEREOFJune 2022September 2023Allow1401YesNo
17851947ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOFJune 2022February 2023Allow801YesNo
17845916CD200 INHIBITORS AND METHODS OF USE THEREOFJune 2022February 2023Allow801YesNo
17725623HUMANIZED ANTl-CD19 ANTIBODY AND USE THEREOF WITH CHIMERIC ANTIGEN RECEPTORApril 2022January 2025Allow3301YesNo
17681268NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERSFebruary 2022May 2025Abandon3901NoNo
17652471METHOD OF SELECTION FOR TREATMENT OF SUBJECTS AT RISK OF INVASIVE BREAST CANCERFebruary 2022September 2023Allow1821YesNo
17581085TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODYJanuary 2022June 2025Allow4111YesNo
17573657CORONAVIRUS-BINDING MOLECULES AND METHODS OF USE THEREOFJanuary 2022January 2024Abandon2401NoNo
17570933THERAPEUTIC AGENTS AND USES THEREOFJanuary 2022April 2025Allow3911YesNo
17565994THERAPEUTIC MUSK ANTIBODIESDecember 2021September 2022Allow901YesNo
17554329NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERSDecember 2021February 2025Allow3821NoNo
17553953NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERSDecember 2021March 2022Allow300NoNo
17554283NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERSDecember 2021April 2025Allow3921NoNo
17552862METHODS AND COMPOSITION FOR A BINDING MOLECULE TARGETING CANCER CELLS EXPRESSING SSX2 PEPTIDE 41-49 IN HLA-A*0201 CONTEXTDecember 2021October 2024Allow3411YesNo
17547315NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERSDecember 2021February 2022Allow200YesNo
17546983ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND USES THEREOFDecember 2021August 2024Allow3220YesNo
17541560NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERSDecember 2021March 2025Allow3921NoNo
17541537NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERSDecember 2021November 2022Allow1100NoNo
17541555NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERSDecember 2021January 2025Allow3721NoNo
17534916ANTI-TIGIT ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICSNovember 2021April 2024Allow2901YesNo
17533784FUSION PROTEINS TARGETING TUMOUR ASSOCIATED MACROPHAGES FOR TREATING CANCERNovember 2021November 2024Abandon3501NoNo
17529322NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERSNovember 2021November 2024Allow3621NoNo
17530072ANTI-HLA-G ANTIBODIES, COMPOSITIONS COMPRISING ANTI-HLA-G ANTIBODIES AND METHODS OF USING ANTI-HLA-G ANTIBODIESNovember 2021November 2024Allow3601YesNo
17517934PLECTIN-1 BINDING ANTIBODIES AND USES THEREOFNovember 2021March 2025Abandon4011NoNo
17514903COMPOSITIONS FOR TARGETING SARS-COV-2 SPIKE PROTEIN RECEPTOR BINDING DOMAINOctober 2021February 2024Allow2811YesNo
17606246CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USEOctober 2021August 2024Allow3411YesNo
17451607BREAST AND OVARIAN CANCER VACCINESOctober 2021April 2024Allow3001YesNo
17502686PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERSOctober 2021January 2022Allow300NoNo
17442720GENETICALLY ENGINEERED DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR AND USE THEREOFSeptember 2021December 2024Allow3911YesNo
17478497LAG-3 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL APPLICATION THEREOFSeptember 2021January 2024Allow2801YesNo
17474894IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODSSeptember 2021October 2024Allow3721NoNo
17471754IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODSSeptember 2021March 2024Allow3011YesNo
17470778T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULESSeptember 2021May 2024Allow3311YesNo
17459133CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPESAugust 2021January 2025Abandon4101NoNo
17405650COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOFAugust 2021March 2022Allow700YesNo
17405246COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOFAugust 2021November 2021Allow300YesNo
17402262COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGETAugust 2021January 2024Allow2910NoNo
17397559ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOFAugust 2021June 2024Allow3421YesNo
17394556ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIESAugust 2021April 2024Abandon3201NoNo
17392075IL-7R-alpha SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIAAugust 2021March 2025Allow4411NoNo
17310296MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO CCSP-2 AND USE THEREOFJuly 2021October 2024Allow3911YesNo
17384894METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERSJuly 2021October 2024Abandon3920NoNo
17384602TUMOR CELL-DERIVED MICROVESICLESJuly 2021March 2025Abandon4311NoNo
17372961HUMANIZED ANTI-AXL ANTIBODIESJuly 2021July 2024Allow3611YesNo
17369169SINGLE DOMAIN ANTIBODY AND DERIVATIVE PROTEINS THEREOF AGAINST CTLA4July 2021November 2023Allow2801YesNo
17366958A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSJuly 2021October 2021Allow300YesNo
17366885A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSJuly 2021April 2024Allow3421NoNo
17364531ESOPHAGEAL CANCER MARKER AND USE THEREOFJune 2021March 2024Abandon3201NoNo
17304823BREAST AND OVARIAN CANCER VACCINESJune 2021September 2021Allow300YesNo
17418475FUSION PROTEIN OF ANTIBODY THAT RECOGNIZES CANCER CELLS AND MUTANT STREPTAVIDINJune 2021November 2024Abandon4101NoNo
17345033COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC MACULAR EDEMAJune 2021April 2024Allow3511YesNo
17340102CONDITIONAL INTERNALIZATION OF PEGYLATED AGENTS BY PRETARGETING BI-SPECIFIC PEG-BINDING ANTIBODIES FOR DIAGNOSIS AND THERAPYJune 2021October 2024Abandon4121NoNo
17331344ANTI-HUMAN LAG-3 ANTIBODIES AND THEIR USE IN IMMUNOHISTOCHEMISTRY (IHC)May 2021January 2023Allow2001YesNo
17328597ANTIBODIES TO M(H)DM2/4 AND THEIR USE IN DIAGNOSING AND TREATING CANCERMay 2021April 2022Allow1000YesNo
17327193NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERSMay 2021May 2024Allow3621NoNo
17294582ETANERCEPT VARIANTS WITH IMPROVED THERAPEUTICAL EFFECTMay 2021December 2024Allow4311YesNo
17314650NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERSMay 2021October 2023Allow2911YesNo
17314668NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERSMay 2021February 2024Allow3321YesNo
17314688NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERSMay 2021October 2023Allow3011YesNo
17308691PROTEINS BINDING NKG2D, CD16 AND CLEC12AMay 2021July 2024Allow3821YesNo
17289810DOSING REGIMEN OF ANTI-LAG3 ANTIBODY AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODY FOR TREATING CANCERApril 2021June 2025Allow4921YesNo
17229592IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODSApril 2021June 2021Allow200YesNo
17284617TREATMENT AND PREVENTION OF MALARIAApril 2021April 2025Allow4811YesNo
17226153COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOFApril 2021June 2021Allow300YesNo
17205634Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint InhibitorMarch 2021June 2024Abandon3911NoNo
17174019METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORSFebruary 2021March 2024Abandon3701NoNo
17087765ANTIBODIES TARGETING QUIESCIN SULFHYDRYL OXIDASE (QSOX1) AND USES OF SAMEFebruary 2021November 2023Abandon3601NoNo
17165833TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGENFebruary 2021July 2024Abandon4211NoNo
17158474ANTI-HUMAN 4-1BB ANTIBODIES AND USES THEREOFJanuary 2021August 2023Allow3111YesNo
17150617NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERSJanuary 2021April 2021Allow300YesNo
17149381A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSJanuary 2021March 2021Allow200YesNo
17149397A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSJanuary 2021August 2023Allow3111YesNo
17149241A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSJanuary 2021July 2023Allow3010YesNo
17144853ANTIBODIES SPECIFIC TO TROPHOBLAST ANTIGEN 2 (TROP2)January 2021October 2024Abandon4501NoNo
17131713HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2December 2020May 2023Allow2801YesNo
17129096COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITORDecember 2020December 2023Abandon3510NoNo
17123865ANTI-RSPO3 ANTIBODIES AND METHODS OF USEDecember 2020October 2023Abandon3401NoNo
17121541Anti-Transglutaminase 2 AntibodiesDecember 2020March 2023Allow2701YesNo
17116845NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERSDecember 2020February 2021Allow200YesNo
17114193CD200 INHIBITORS AND METHODS OF USE THEREOFDecember 2020June 2023Allow3111YesNo
17103318Reagents and Methods for Monitoring Breast Cancer TherapyNovember 2020June 2024Abandon4311NoNo
16950645METHODS FOR INHIBITING ANGIOGENESIS IN A SUBJECT IN NEED THEREOFNovember 2020January 2024Allow3811YesNo
17056384METHODS OF ISOLATING ALLERGEN-SPECIFIC ANTIBODIES FROM HUMANS AND USES THEREOFNovember 2020May 2024Allow4211YesNo
17055561COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOFNovember 2020May 2024Abandon4201NoNo
17096750ANTI-CANCER FUSION POLYPEPTIDENovember 2020June 2024Allow4421YesNo
17094495USE OF MARIZOMIB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERSNovember 2020January 2024Allow3821YesNo
17052960ANTIBODIES SPECIFIC TO HUMAN NECTIN4November 2020April 2024Allow4211YesNo
17086817METHOD FOR IMPROVED DIAGNOSIS OF DYSPLASIASNovember 2020March 2023Abandon2930YesYes
17048490REPROGRAMMING CD4 T CELLS INTO CYTOTOXIC CD8 CELLS BY FORCED EXPRESSION OF CD8aB AND CLASS 1 RESTRICTED T CELL RECEPTORSOctober 2020March 2025Allow5311YesNo
17072612COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER OR INFECTIONOctober 2020March 2023Allow2901YesNo
17070623ANTIBODY MOLECULE FOR HUMAN GM-CSF RECEPTOR ALPHAOctober 2020May 2024Abandon4301NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner YAO, LEI.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
14
Examiner Affirmed
9
(64.3%)
Examiner Reversed
5
(35.7%)
Reversal Percentile
56.0%
Higher than average

What This Means

With a 35.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
115
Allowed After Appeal Filing
25
(21.7%)
Not Allowed After Appeal Filing
90
(78.3%)
Filing Benefit Percentile
25.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 21.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner YAO, LEI - Prosecution Strategy Guide

Executive Summary

Examiner YAO, LEI works in Art Unit 1642 and has examined 1,137 patent applications in our dataset. With an allowance rate of 56.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner YAO, LEI's allowance rate of 56.2% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by YAO, LEI receive 1.70 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by YAO, LEI is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +70.1% benefit to allowance rate for applications examined by YAO, LEI. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 24.1% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 32.9% of cases where such amendments are filed. This entry rate is in the 40% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 76.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 78.8% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 76.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 61.2% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.9% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 59% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.